Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-center, single-arm clinical trial of penpulimab (AK105) combined with anlotinib hydrochloride and epirubicin in the first-line treatment of soft tissue sarcoma

Next Previous
Trial Profile

A multi-center, single-arm clinical trial of penpulimab (AK105) combined with anlotinib hydrochloride and epirubicin in the first-line treatment of soft tissue sarcoma

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Catequentinib (Primary) ; Epirubicin (Primary) ; Penpulimab (Primary)
  • Indications Haemangiosarcoma; Leiomyosarcoma; Liposarcoma; Nerve sheath neoplasms; Rhabdomyosarcoma; Sarcoma; Soft tissue sarcoma; Synovial sarcoma
  • Focus Therapeutic Use

Most Recent Events

  • 06 Jun 2023 Results (n=32, as of data cut off date of December 20, 2022) presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
  • 27 Oct 2022 New trial record
  • 13 Sep 2022 Results (data cutoff in Apr 2022) from phase I dose escalation ,presented at the 47th European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top